Crystalline forms of n-[2-[[(2,3-difluorophenyl)methyl]thio]-6--4-pyrimidinyl]-1-azetidinesulfonamide
AssigneeAstraZeneca AB
InventorsBritt Anne Ingela Gullberg, Thomas Peter Larsson, Jeffrey Paul Stonehouse
Life of this patent
Estimating the term…
Abstract
There is provided crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfon-amide anhydrate. Such compounds/forms may be useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
Claims16
A crystalline form of N-[2-[[(2,3-di:fluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfon-amide (also referred to as “Compound I”), characterised by a powder X-ray diffraction pattern, measured using a wavelength of X-rays 1.5418 A, comprising at least one crystalline peak with a 2-Theta value (in degrees) of 21.0, 28.8 and/or 29.1.
A crystalline form of Compound I, characterised by a powder X-ray diffraction pattern, measured using a wavelength of X-rays 1.5418 A, comprising at least one crystalline peak with a 2-Theta value (in degrees) of around 12.9, 18.0 and/or 21.0.
A crystalline form of Compound, I which has a melting point (onset) of 152.7° C.
Dependencies are inferred from the claim text.